StockData
Ligand Pharmaceuticals Inc logo

Ligand Pharmaceuticals Inc (LGND) stock

LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 6/30446% above fair value
$293.81−7.90 (-2.62%)

Close on Nov 17, 2026Market cap $5.88BP/E 128.3Yield –

Ligand Pharmaceuticals Inc grew revenue 1.0% to $253.83M over the twelve months to Sep 30, 2026. Operating income rose 41.9% to $25.52M, moving the operating margin from 7.2% to 10.1%. Free cash flow was $90.63M, up 194.6% from a year earlier. At the latest close the market valued the company at $5.88B, 128.3 times its earnings.

Revenue
$253.83M
+1.0% vs. a year earlier
Operating income
$25.52M
+41.9% vs. a year earlier
Free cash flow
$90.63M
+194.6% vs. a year earlier
EPS, diluted
$2.29
+18.7% vs. a year earlier

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026

Valuation

Market cap
$5.88B
P/E ratio
128.3
Price to sales
23.15
Price to book
6.11
Dividend yield
–
Free cash flow yield
1.54%

Fundamentals

Revenue
$253.83M
Net income
$51.46M
EPS, diluted
$2.29
Free cash flow
$90.63M
Book value per share
$48.18
Diluted shares
20M

Trading

Next earnings
Feb 25, 2027 (estimated, before the open)
Previous close
$301.71
Open
$300.26
Day's range
$291.61 – $302.02
Volume
293,655
Average volume (20 days)
224,253
Index membership
S&P SmallCap 600 (since Nov 2021), Russell 2000, Russell 3000
52-week range
$175.89 – $326.63
RSI (14 days)
45.8
Volatility (1 year)
36.6%
Relative volume
0.78×

On 1 of our idea list: Institutions accumulating

Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.

Market cap history

Month-end market cap since 2010, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.

PeriodLGNDS&P 500DifferenceLGND per yearS&P 500 per year
1 month-0.6%-4.0%+3.5 pts
3 months+0.7%-5.0%+5.7 pts
Year to date+55.4%+8.2%+47.2 pts
1 year+45.9%+11.2%+34.7 pts
3 years+408.1%+68.5%+339.7 pts+71.9%+19.0%
5 years+190.7%+67.3%+123.4 pts+23.8%+10.8%
10 years+346.3%+291.6%+54.6 pts+16.1%+14.6%

Fifteen years at a glance

Fiscal years 2011 to 2025 and trailing twelve months, USD

Revenue

$253.83M+1.0% YoY

Gross profit

–

Operating income

$25.52M+41.9% YoY

Net income

$51.46M+5.9% YoY

EPS, diluted

$2.29+18.7% YoY

Free cash flow

$90.63M+194.6% YoY
Reported periodTrailing twelve months

Press releases

Releases Ligand Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Ligand Pharmaceuticals

Pharmaceutical Preparations

Ligand Pharmaceuticals is a biopharmaceutical company focused on developing and licensing biopharmaceutical assets, royalty assets, and related technologies. Its business model centers on acquiring, creating, and managing financial and intangible royalty rights across various drug development programs and partnered commercial therapies, alongside selling proprietary materials such as Captisol. The company enters into development and licensing agreements, service contracts, and collaborative partnerships with global biopharmaceutical firms and research partners to advance clinical-stage candidates and marketed products.

Company profile, executives and history

Ligand Pharmaceuticals stock: common questions

What is Ligand Pharmaceuticals's stock price?

LGND closed at $293.81 on Nov 17, 2026, down 2.62% on the day. Over the past 52 weeks it traded between $175.89 and $326.63.

What is Ligand Pharmaceuticals's market cap?

Ligand Pharmaceuticals was worth $5.88B at the close on Nov 17, 2026: the share price times the diluted shares outstanding.

What is LGND's P/E ratio?

LGND trades at 128.3 times earnings, based on diluted earnings per share of $2.29 over the twelve months to Sep 30, 2026.

How much revenue does Ligand Pharmaceuticals make?

Ligand Pharmaceuticals reported revenue of $253.83M for the twelve months to Sep 30, 2026, up 1.0% from a year earlier.

Does Ligand Pharmaceuticals pay a dividend?

No. Ligand Pharmaceuticals has not paid a cash dividend over the last twelve months.

When does Ligand Pharmaceuticals report earnings next?

Ligand Pharmaceuticals is expected to report Q4 FY2026 results on Feb 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.

How has LGND stock performed over the past year?

Including dividends, LGND returned +45.9% over the past year, against +11.2% for the S&P 500.

Who are Ligand Pharmaceuticals's competitors?

Companies most similar to Ligand Pharmaceuticals by business, industry and size include KPTIQ, AAPG, ANAB, AMRN, SDGR.

See a number that looks wrong?